EMA takes action to bar Richter’s Esmya

Gedeon Richter has vowed to work with the European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC), and insisted it “takes patient safety seriously”, after the committee advised that no new patients start taking the Esmya (ulipristal acetate) women’s healthcare brand until it completes a safety evaluation.